PMID- 35064722 OWN - NLM STAT- MEDLINE DCOM- 20220523 LR - 20220909 IS - 1879-0844 (Electronic) IS - 1388-9842 (Linking) VI - 24 IP - 5 DP - 2022 May TI - Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real-world multicentre experience. PG - 899-907 LID - 10.1002/ejhf.2434 [doi] AB - AIMS: Transcatheter mitral valve implantation (TMVI) is a new treatment option for patients with symptomatic mitral valve (MV) disease. Real-world data have not yet been reported. This study aimed to assess procedural and 30-day outcomes of TMVI in a real-world patient cohort. METHOD AND RESULTS: All consecutive patients undergoing implantation of a transapically delivered self-expanding valve at 26 European centres from January 2020 to April 2021 were included in this retrospective observational registry. Among 108 surgical high-risk patients included (43% female, mean age 75 +/- 7 years, mean STS-PROM 7.2 +/- 5.3%), 25% was treated for an off-label indication (e.g. previous MV intervention or surgery, mitral stenosis, mitral annular calcification). Patients were highly symptomatic (New York Heart Association [NYHA] functional class III/IV in 86%) and mitral regurgitation (MR) was graded 3+/4+ in 95% (38% primary, 37% secondary, and 25% mixed aetiology). Technical success rate was 96%, and MR reduction to